908 Devices Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
908 Devices reported Q2 2026 revenue of $16.1M (23% YoY growth) and raised full-year guidance to $68.0M–$70.0M (from $67.0M–$70.0M), implying 21–25% growth. Adjusted EBITDA loss improved to −$1.9M from −$3.9M YoY. The company spent $13.5M to acquire NIRLab SA and holds $101.5M cash with no debt. Installed base grew 23% YoY to 4,101 devices; recurring revenue was 31% of Q2 revenue ($4.9M).
Why this rating
Revenue growth of ~23% and guidance raise are solid for a ~$195M-cap biotech instrumentation company, but company still unprofitable on GAAP basis (−$11.9M loss Q2). NIRLab acquisition ($13.5M) is meaningful relative to size but funded from cash. Modest Adjusted EBITDA improvement shown.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.